PMID- 23673101
OWN - NLM
STAT- MEDLINE
DCOM- 20131213
LR  - 20220330
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Linking)
VI  - 126
IP  - 10
DP  - 2013
TI  - Etoricoxib versus indometacin in the treatment of Chinese patients with acute 
      gouty arthritis: a randomized double-blind trial.
PG  - 1867-71
AB  - BACKGROUND: Acute gout is an intensely painful, inflammatory arthritis. Although 
      the non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for this 
      condition, the efficacy is based on only a few studies, particularly in China. We 
      tried to assess the safety and efficacy of etoricoxib in the treatment of acute 
      gouty arthritis in China. METHODS: A randomized, double-blind, active comparator 
      study was conducted at 10 sites in China. Patients (n = 178; >/= 18 years of age) 
      with acute gouty attack (< 48 hours) were treated for 5 days with etoricoxib (120 
      mg/d; n = 89) or indometacin (75 mg twice daily; n = 89). The primary efficacy 
      end point was self-assessed pain in the affected joint (0-4 point Likert scale) 
      from days 2 - 5. Secondary end points included investigator assessments of 
      tenderness and swelling, patient/ investigator global assessments of response to 
      therapy, and patients discontinuing treatment. Safety was assessed by adverse 
      events (AEs). RESULTS: Etoricoxib and indometacin had comparable primary and 
      secondary end points. Mean change difference from baseline from days 2 - 5 was 
      0.03 (95% confidence interval (CI) -0.19 to 0.25; P = 0.6364), which fell within 
      the prespecified comparative bounds of -0.5 to 0.5. No severe AEs were associated 
      with etoricoxib use. Non-severe AEs were mainly digestive and general, and most 
      (73.7%) were mild, although they caused withdrawal of two subjects in the 
      etoricoxib group, due to bilateral renal calculi and uronephrosis of the left 
      kidney (unrelated to etoricoxib) and fever and chills (potentially 
      etoricoxib-related). Overall, AEs were similar, although the absolute number of 
      AEs in the etoricoxib group (n = 31) was less than the indometacin group (n = 
      34). CONCLUSIONS: Etoricoxib (120 mg once daily) is effective in treating acute 
      gout, is generally safe and well-tolerated, and is comparable in efficacy to 
      indometacin (75 mg twice daily).
FAU - Li, Ting
AU  - Li T
AD  - Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School 
      of Medicine, Shanghai 200001, China.
FAU - Chen, Shun-le
AU  - Chen SL
FAU - Dai, Qing
AU  - Dai Q
FAU - Han, Xing-Hai
AU  - Han XH
FAU - Li, Zhan-Guo
AU  - Li ZG
FAU - Wu, Dong-Hai
AU  - Wu DH
FAU - Zhang, Xiao
AU  - Zhang X
FAU - Gu, Jie-Ruo
AU  - Gu JR
FAU - Yang, Nan-Ping
AU  - Yang NP
FAU - Sun, Ling-Yun
AU  - Sun LY
FAU - Zhang, Miu-Jia
AU  - Zhang MJ
FAU - Li, Xing-Fu
AU  - Li XF
FAU - Bao, Chun-de
AU  - Bao CD
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Pyridines)
RN  - 0 (Sulfones)
RN  - WRX4NFY03R (Etoricoxib)
RN  - XXE1CET956 (Indomethacin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Arthritis, Gouty/*drug therapy
MH  - Cyclooxygenase Inhibitors/adverse effects/*therapeutic use
MH  - Double-Blind Method
MH  - Etoricoxib
MH  - Female
MH  - Humans
MH  - Indomethacin/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Pyridines/adverse effects/*therapeutic use
MH  - Sulfones/adverse effects/*therapeutic use
EDAT- 2013/05/16 06:00
MHDA- 2013/12/18 06:00
CRDT- 2013/05/16 06:00
PHST- 2013/05/16 06:00 [entrez]
PHST- 2013/05/16 06:00 [pubmed]
PHST- 2013/12/18 06:00 [medline]
PST - ppublish
SO  - Chin Med J (Engl). 2013;126(10):1867-71.